Tinzaparin.
Low-molecular-weight heparins (LMWH) are efficacious agents that offer clinical and pharmacoeconomic advantages over unfractionated heparin (UFH) for the treatment of ACS and venous thromboembolism. Tinzaparin is a LMWH approved for the treatment of deep venous thrombosis with and without pulmonary embolism, when used in conjunction with warfarin. In studies with hospitalized patients who had deep venous thrombosis or pulmonary embolism, tinzaparin was at least as efficacious as UFH, with fewer adverse bleeding events. It is also efficacious for thromboembolic prophylaxis in patients undergoing general and orthopedic surgery. Studies have shown that tinzaparin is at least as effective as UFH for patients undergoing surgery and in other patients at risk for developing thromboembolism. It is currently not recommended for use in patients with ischemic strokes. There are minimal data available regarding its use in the management of patients with unstable angina (UA) and non-ST-segment elevation myocardial infarction.
D000789:Angina, Unstable / Q000188:drug therapy; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000191:economics / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000737:chemistry / Q000191:economics / Q000494:pharmacology*; D006801:Humans; D015394:Molecular Structure; D009203:Myocardial Infarction / Q000188:drug therapy; D020521:Stroke / Q000188:drug therapy; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin